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ABSTRACT 
Alzheimer’s disease (AD) is a destructive neurodegenerative disorder characterized by progressive memory defeat and impairment in behavior, 
language, and visuospatial skills. Neuropsychiatric symptoms such as apathy, depression, aggression, agitation, sleep disruption, and psychosis are 
now recognized as core symptoms of AD that are expressed to varying degrees throughout the course of disease. The neuro pathological features of 
AD comprise extracellular senile plaques constituted of β-amyloid (Aβ) pledges, intracellular neurofibrillary tangles (NFTs), and cerebral atrophy; 
others include apolipoprotein E, oxidative stress, mitochondrial dysfunction and cholinergic hypothesis. Anti-amyloid therapy is available for the 
treatment of Alzheimer’s disease, others are anticholinergic therapy, and therapy for mitochondrial dysfunction, γ-secretase inhibitors (GSI) and 
modulators (GSM), 𝛽𝛽-secretase (BACE1) inhibitors, Glial modulating drugs includes RAGE receptor antagonists, TNF-α antagonists, neuroprotective 
drugs such as antioxidants, phosphodiesterase inhibitors, PPARγ agonists, and anti-tau or tau modulators like microtubule stabilizers, kinase 
inhibitors. This review includes discussion on neurobiological mechanisms and newly developed compounds which have lesser side effects and are 
proving more efficient for treatment of Alzheimer’s disease. 
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INTRODUCTION 
Alzheimer’s disease (AD) is a critical neurodegenerative illness 
characterized by memory loss and diminished performance, 
language, and visuospatial skills [1]. Epidemiological data show 
that the occurrence of AD increases with age and doubles every 5 y 
after 65 y of age [2, 3]. There were about 26.6 million cases of AD 
in the world in 2006 and it is predictable that the worldwide 
dominance of AD will grow fourfold to 106.8 million by the year 
2050 [4]. The neuropathological features of AD involve 
extracellular senile plaques constituted of β-amyloid (Aβ) pledges, 
intracellular neurofibrillary tangles (NFTs), and cerebral atrophy 
[5]. Aβ, produced from the proteolytic administration of amyloid 
precursor protein (APP), has been projected to have a causative 
role in the generation of AD and this Accumulated Amyloid-β can 
provoke euro-toxicity by generating oxidative stress and 
inflammation in the brain [6, 7]. 
Causative factors 
Both non-modifiable and modifiable risk factors are involved in AD. 
Non-modifiable factors include age which is one of the important 
risk factors, genes, family history, Down’s syndrome while 
modifiable factors include cognitive engagement, diet/nutritional 
supplement intake, physical activity level, type 2 diabetes, alcohol 
consumption, mood disorders, hypertension, hypercholesterolemia, 
and smoking [8-11]. 
Genetic factors 
Alzheimer’s disease happens in both familial and an irregular form, 
also recognized as early onset or late onset Alzheimer's disease 
(LOAD), respectively [12]. Early-onset domestic AD is generally 
produced by autosomal dominant variations in the genes for 
amyloid precursor protein (APP), presenilin 1 and presenilin 2. This 
form of AD accounts for around 2–5% of all AD cases [13]. The 
apoE4 allele is the single verified heritable factor in the progress of 
together the early and late-onset practices of AD. This factor rises 
vulnerability to AD however it is neither essential nor adequate for 
the progress of this disease. In late-onset irregular form, greater the 
number of the apoE4 alleles, the greater the possibility of AD and the 
lesser the age of onset. The risk influence of the occurrence of the 
apoE4 allele declines with age. Usually, around 15-20% of AD cases 
could be recognized to this risk [14]. 
Vascular factors 
Smoking 
Smoking is a well-recognised cardiac risk factor and facilitates 
oxidative stress, inflammation and atherosclerosis which are 
identified as the risk factors for neurodegeneration [15]. Oxidative 
stress promotes augmented β-secretase cleavage of APP and 
abnormal tau phosphorylation. It may openly enable the 
amyloidogenic pathway involved in Aβ oligomer invention and 
extracellular fibrillar Aβ aggregation, as well as abnormal tau 
phosphorylation [16]. 
Alcohol 
It is well predictable that alcohol abuse causes alcohol dementia. In 
heavy consumers, alcohol causes injuries in the brain. Light to 
adequate alcohol intake is found to be closely associated with brain 
atrophy and volume loss [17, 18]. 
Obesity 
It has been showed that being obese contributes to dementia and 
cerebral decay. Obesity leads to dementia, cerebral damage and 
consistent neurological modifications [19]. 
Blood pressure and management of hypertension 
High blood pressure is one of the most significant manageable risk 
factors for stroke, which in turn can result in vascular dementia. It 
has been reported that there is a close relationship between AD and 
hypertension [20]. It has been recently proved that antihypertensive 
drugs have a protective effect against the progress of dementia and AD 
[21-23]. The antihypertensive remedy may protect against dementia 
and AD by decaying the atherosclerotic process, reducing the number 
of atherosclerotic scratches and improving cerebral perfusion [24]. 
Diabetes mellitus 
It has been reported that there is an increased risk of vascular 
dementia in persons with diabetes [25-27]. Binding of insulin or IGF-
1 causes a conformational variation of the receptor leading to their 
autophosphorylation on definite tyrosine residues on the β-subunit 
resulting in activation of the insulin receptor substrate-1 (IRS-1) 
[28, 29]. The latter, in turn, stimulates two main signaling pathways: 
initially the PI3K pathway, which is involved in the preservation of 
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synaptic plasticity and memory consolidation [30], Aβ-induced 
memory loss [31], and synthesis of nitric oxide (NO),which in turn 
plays a role in learning and memory practices[32]; and second 
pathway contains the MAPK cascade, which is accountable both for 
the induction of several genes essential for neuronal and synapse 
development, conservation and healing processes, as well as serving 
as a modulator of hippocampal synaptic plasticity that motivates 
learning and memory [33]. 
Hypercholesterolemia and statin therapy 
High total serum cholesterol levels in medium age are involved to be 
a risk factor for the progress of AD at a later age [34, 35]. High total 
cholesterol in medium age is a risk factor for the progress of AD and 
additional dementias 20 y later but declining serum cholesterol 
levels in late medium age may be due to continuing disease progress 
and may characterize a sign for later AD and other dementias [36]. 
Statins have been reported to decline the production of β-amyloid. 
Statins also have several other effects that may be valuable for the 
CNS and thus, may smaller the risk of AD [37, 38]. 
Nutritional factors 
Consumption of antioxidants such as vitamin E and vitamin C 
decreases the risk of developing AD. It has been reported that diet 
rich in saturated fats and cholesterol increases the risk of AD [39-
41]. Antioxidants in turn decrease the oxidative stress and amyloid 
beta-peptide (A𝛽𝛽) accumulation [42, 43]. Antioxidants, vitamins, 
polyphenol, polyunsaturated fatty acids, fish, fruits, vegetables, tea, 
and light to moderate intake of alcohol are useful for AD, while 
trans-fatty acids, saturated fatty acids, carbohydrates, and whole-fat 
dairy are harmful to AD[44]. 
Psychosocial factors 
It was found that psychosocial factors and a vigorous lifestyle during 
life may decline the risk of dementias including AD [45]. 
Education and socioeconomic status 
The risk for dementia is minor for those with higher education, 
occupational achievement, intelligence or IQ and cerebrally exciting 
leisure events [46]. Lower education is tied to enlarged risk of 
dementia and AD [47, 48]. It has been reported that a poor social 
network or a lack of social commitment are related with reduced 
cognitive functions and dementia [49]. The risk of dementia is also 
higher in elderly individuals with increased social segregation and 
less numerous and inadequate contacts with families and friends. 
Individuals with low neuroticism joined with high extraversion had 
a lower risk of dementia [50]. Low levels of social commitment in 
late life and declined social commitment from medium to late life are 
associated with a two-fold increase in the risk of the progress of 
dementia and AD later in life [51, 52]. 
Physical and mental activity 
It has been reported that midlife physical activity may be linked with 
a reduced risk of AD or vascular dementia in later life [53]. Physical 
activity is assumed to enrich cognitive function by increasing cardiac 
suitability and cerebral perfusion and probably by stimulating 
neurogenesis [54]. Numerous activities necessitating mental 
exertion such as reading, social and traditional activities, indicate a 
defensive effect against dementia and AD [55, 56]. It has been 
proved recently that complex cerebral activity across lifecycle leads 
to reduced hippocampal atrophy [57]. 
Pathophysiology of AD 
Two of the symbol neuro pathologic outcomes in AD are extracellular 
amyloid and neuritic plaques and intracellular neurofibrillary tangles. 
Amyloid-β and tau proteins 
According to the amyloid theory, A𝛽𝛽 peptide massing in patient’s 
brain is the crucial event leading to the progress of AD. It has been 
reported in the in-vitro studies that the incubation of the Aβ peptide 
with cells in culture persuades a neurotoxic consequence 
characterized by oxidative stress, apoptosis, and injury to 
membrane and cytoplasmic proteins, mitochondrial DNA, and lipids 
[58, 59]. Amyloid plaques are mainly formed by accretion of 
insoluble Aβ peptides, while neurotic plaques are composed of 
insoluble Aβ peptides in deteriorated neurites (dendrites, axons, or 
telodendria), and some comprise hyper phosphorylated tau proteins 
(p-tau) [60].  
In AD, the tau protein undertakes oligomerization and forms paired 
helical filaments (PHFs), which then leads to the progress of NFT 
[61]. It has been reported that tau persuades mitochondrial dysfunction, 
leading to severe energy dysfunction and the generation of ROS and 
reactive nitrogen species (RNS) [62], disturb the integrity of biological 
membranes and leads to synaptic failure [63], which is characterized by 
synaptic degradation, and neuronal loss [64, 65]. 
Apolipoprotein E 
The Apolipoprotein E (Apo E) is a significant protein involved in 
preserving the structural and functional integrity of synapses and 
membranes [66]. There are three iso forms: ApoE2 (Cys112, 
Cys158), ApoE3 (Cys112, Arg158), and ApoE4 (Arg112, Arg158) 
[67]. The E4 allele confers an augmented risk; however the e2 allele 
decreases the risk. ApoE4 may increase the intracellular 
reprocessing of APP, which could raise A𝛽𝛽 production [68]. 
Modifications in complement signaling pathways may affect 
microglia function resulting in reduced capability to phagocytize 
apoptotic cells and clear beta-amyloid [69]. 
 
 
Fig. 1: Effect of oxidative stress in lipid peroxidation and protein modification in AD [82] 
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Role of oxidative stress in AD 
Oxidative stress results due to an imbalance between the production 
and quenching of free radicals from oxygen species [70]. Enhanced 
ROS assembly or decreased antioxidant system leads to oxidative 
imbalance and cause ROS overproduction [71-73]. The process of 
aging is also related with augmented oxidative stress [74]. It has 
been reported that oxidative stress plays a vital role in the 
pathogenesis of AD leading to neuronal dysfunction and cell loss 
[75]. As lipid peroxidation is significantly augmented in AD. Lipid 
peroxidation is the process in which lipids are attacked by ROS 
through a free radical chain reaction mechanism to produce lipid 
peroxidation products. It has been reported that the 4-hydroxynonal 
levels are considerably raised in the hippocampus, entorhinal cortex, 
temporal cortex, amygdala, parahippocampal gyrus in AD. Oxidative 
amendments in proteins occur which are the outcome of direct ROS 
attack or from reaction with glycation, glycoxidation, and lipid 
peroxidation product binding [76, 77]. Oxidative impairment of 
DNA/RNA has been reported in AD. Oxidative impairment of DNA 
can cause DNA double strand disruptions, DNA/DNA or 
DNA/protein crosslinking, and base alteration (see in figure1). It has 
been reported that high levels of DNA breakdowns were established 
in the hippocampus and cerebral cortex in AD [78,79]. It has been 
reported that an increase of oxidative biomolecule products and 
reduction in antioxidant levels or antioxidant enzyme action leads to 
AD [80]. The decreased plasma levels of antioxidants such as 
albumin, bilirubin, uric acid, lycopene, vitamin A, vitamin C, and 
vitamin E has been reported in AD patients [81]. 
Mitochondrial dysfunction 
Mitochondria are responsible for ATP production, signaling pathway 
and cell activities. They are also involved in apoptosis and in 
dynamic movements essential for precise respiratory activity and 
metabolic efficiency through fusion/fission [83]. Dysfunctional 
mitochondria are less effective producers of ATP but more effective 
producers of ROS, signifying the main source of oxidative imbalance 
as detected in AD [84, 85]. It has been reported that mitochondrial 
dysfunction is a prominent and primary feature of AD [86]. 
Furthermore, mitochondrial dysfunction results in diminished 
features of mitochondrial function in AD [87]. Dysfunctional 
mitochondria cause high levels of ROS that may be noxious for 
neurons [88]. Moreover, ROS treats mitochondria as a target 
triggering oxidation of its constituents such as mtDNA, lipids, and 
proteins which finally results in mitochondrial worsening [89]. 
Declined calcium uptake and increased calcium burden leads to 
calcium deregulation and enlarged intracellular calcium in the brain 
[90-92]. Furthermore, mitochondrial dysfunction has been reported 
to modify the levels of numerous enzymes which contain pyruvate 
dehydrogenase and 𝛼𝛼-ketoglutarate dehydrogenase ATP-citrate 
lyase, and acetoacetyl-CoA thiolase. Reduced levels of these enzymes 
results in diminish production of acetyl-coA which causes deficit 
cholinergic expressions in AD patients [93-100]. ROS action on 
mitochondria generate toxic products like hydroxynonenal which 
facilitate the self-assembly of tau proteins into helical filaments 
which are reported to be present in AD [101]. 
Cholinergic hypothesis 
There is a prominent and inconsistent insufficiency of acetylcholine. 
The functional basis of the cholinergic shortage is the atrophy and 
worsening of subcortical cholinergic neurons, mainly those in the 
basal forebrain (nucleus basalis of Meynert), that provide 
cholinergic innervation to the entire cerebral cortex. The selective 
insufficiency of acetylcholine in AD, results in dementia in AD, has 
given rise to “cholinergic hypothesis,” which recommends that a lack 
of acetylcholine is critical in the origin of the signs of AD. In AD, 
there is not only damage of cholinergic neurons but also the cortical 
and hippocampus areas that receive cholinergic input [102].  
Signs and symptoms of AD 
Neuropsychiatric symptoms such as apathy, depression, violence, 
anxiety, sleep interruption, and psychosis are now recognized as the 
main symptoms of AD that are expressed to variable degrees during 
the progression of the disease [103] and finally results in 
Alzheimer’s dementia. 
Diagnosis of AD 
The occurrence and distribution of amyloid plaques and NFT in the 
brain is used to found the finding of ‘definitive’ AD and stage the 
illness [104]. In clinical settings, the diagnosis of AD, is mainly based 
on medical history, somatic and neural examinations, and 
neuropsychological evaluation [105]. Patients with minor cognitive 
damage should be monitored for cognitive and functional decay 
because of their increased risk for dementia. The NINCDS-ADRDA 
conditions for the diagnosis of possible AD or the DSM-III-R 
conditions for dementia of the Alzheimer type should regularly be 
used. Structural neuroimaging and magnetic resonance imaging are 
suitable in the initial evaluation of patients with dementia. [106-108]. 
Recent advances in treatment of AD 
Anti-amyloid therapy 
Anti-amyloid therapy involves the uses of drugs (see in table 1) with 
a different mechanism of actions: (i) enhance the clearance of Aβ; 
(ii) Prevent the production of Aβ; or (iii) Inhibit the accumulation of 
Aβ [109]
 
. Active and passive immunization results in decreased 
levels of intracerebral Aβ burden by inducing humoral reaction 
against the Aβ peptide leading to its clearance from the brain [110]. 
Table 1: Newer compounds targeted to anti-beta-amyloid treatment [111-120] 
Compound Target/Treatment Current phase 
ANI-1792 Vaccine-active immunization Interrupted at phase I (severe side effects such as meningoencephalitis) 
CAD-106 Vaccine-active immunization Phase I (ongoing) 
Bapineuzumab Beta-amyloid monoclonal antibody Phase III (ongoing) 
Solanezumab  Beta-amyloid monoclonal antibody Phase III (ongoing) 
Ponezumab  Beta-amyloid monoclonal antibody Interrupted at phase II (no efficacy) 
Gantenerzumab  Beta-amyloid monoclonal antibody Phase I (ongoing) 
Crenezumab  Beta-amyloid monoclonal antibody Phase I (ongoing) 
Semagacestat  Gamma-secretase inhibitor Interrupted at phase III (no efficacy and risk for skin cancer) 
Avagacestat  Gamma-secretase inhibitor Phase II (ongoing) 
GRL-834 Beta-secretase inhibitor Ongoing 
TAK-070 Beta-secretase inhibitor Ongoing 
CHF-5074 Non-steroid anti-inflammatory agent Ongoing 
DAPT Prototypal Gamma-secretase inhibitor Ongoing 
Curcumin  Anti-amyloid aggregator Ongoing 
 
𝛽𝛽-Secretase (BACE1) inhibitor 
Beta-site APP-cleaving enzyme 1 (BACE1) is a protease responsible 
for cleavage of APP, resulting in generation of assembly of 
neurotoxic irregular A𝛽𝛽[121,122]. Nuclear peroxisome proliferator 
activated receptor gamma (PPAR𝛾𝛾) functions as a transcription 
factor which regulates gene expression [123], promotes microglia-
mediated A𝛽𝛽endocytosis. Also it reduces inflammation response and 
Kaur et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 2, 8-15 
 
11 
causes decreased cytokine excretion [124]. Thiazolidinedione can 
induce PPAR𝛾𝛾 to inhibit 𝛽𝛽-secretase and stimulate ubiquitination to 
worsen amyloid burden [125]. It has been also reported that PPAR𝛾𝛾 
agonist i.e. thiazolidinedione derivatives like rosiglitazone and 
pioglitazone worsens AD neuropathology by reducing insulin 
sensitivity which helps in A𝛽𝛽proteolysis [126]. 
γ-Secretase inhibitors (GSI) and modulators (GSM) 
γ-secretase is a transmembrane protease responsible for cleavage of 
amyloid precursor protein (APP) to produce Aβ [127,128]. Different 
GSIs such as DAPT, L685458 andMRK-560 131have been recently 
developed [129, 130]. While different (GSM) such as avagacestat 
(BMS-708163), begacestat and NIC5-15 are under clinical trials [131]. 
Kinase inhibitors 
The first class of tau inhibitors which helps in targeting tau 
phosphorylation and reduces tau phosphorylation by decreasing the 
activity of kinase enzyme. Interaction between glycogen synthase 
kinase 3 beta (GSK3𝛽𝛽) and protein phosphate 2 (PP2A) augments 
tau hyper phosphorylation and NFT generation [132]. Lithium, 
valproate, NP-031112 (NP-12) and epothilone D (BMS-241027) 
decreases tau phosphorylation and prevent reversed features of 
tauopathy [133-136]. 
Therapy for mitochondrial dysfunction 
Latrepirdine (DIMEBON), an antihistamine which preserves 
mitochondrial structure and function and protects against A𝛽𝛽 induced 
apoptosis is under investigation [137,138]. Its combination with 
donepezil is also under investigation [139]. AC-1204 is considered to 
improve mitochondrial metabolism by inducing chronic ketosis, thereby 
releasing regional cerebral hypometabolism presented in early 
Alzheimer’s disease, and this agent is also under investigation [140]. 
Anticholinergic therapy 
Anticholinergic therapy includes administration of cholinesterase 
inhibitors to treat the cholinergic deficit associated with AD. The 
drugs include tacrine (COGNEXS), donepezil (ARICEPTS), 
rivastigmine (EXELON), and galantamine (REMINYLS) [141]. 
 
Table 2: Overall pharmacologic treatments other than anti-amyloid therapy under research for Alzheimer’s disease [142-144] 
Pharmacologic treatment Agent under research 
Neurotransmitter-based  
Acetylcholine  ST 101, AF 267B, ABT 089, AZD 3480, MEM 3454, EVP-6124, Posiphen, Huperzine 
Serotonin  5-HT4 partial agonists, 5-HT1A agonists/antagonists, 5-HT6 
Norepinephrine/Dopamine:  
antagonists 
MAO A and MAO B inhibitors 
GABA:  GABA-B antagonists 
Glutamate:  AMPA potentiator 
Glycine:  Partial agonists 
Glial modulating drugs:   
Direct glial target:  G and GM CSF, Nitro flurbiprofen, ONO-2506, Tacrolimus 
RAGE receptor antagonist:  TTP 488 
TNF-α antagonist:  Enbrel  
Neuroprotection:   
Antioxidants:  Vitamin C and E, alpha lipoic acid, CoQ10 
Miscellaneous:  PDE inhibitors, PPARγ agonists and insulin, SIRT1 activators, Growth factors (BDNF and NGF), Dimebon 
Anti-tau or tau modulators:   
Microtubule stabilizers:  NAP (AL-108) and Methylene blue (Rember) 
Kinase inhibitors (GSK-3α, GSK-3β, CDK 5) Lithium, AZD-1080, Minocycline 
 PDE-4 inhibitors, immunotherapies 
[GABA, gamma-amino butyric acid; RAGE, receptor for advanced glycation end products; TNF, tumor necrosis factor; GSK, glycogen synthase kinase; 
CDK, cyclic-dependent kinase; 5-HT (4, 1A and 6), 5-hydroxytryptamine (receptor subtypes); MAO (A and B), monoamine oxidase (A and B 
subtypes); AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; PPAR, peroxisome proliferator-activated receptors; SIRT1, 
sirtuin (silent mating type information regulation 2 homolog)-1; BDNF, brain-derived neurotrophic factor; NGF, nerve growth factor; NAP, neuronal 
microtubule-interacting agent (a peptide of eight amino acids, NAPVSIPQ); PDE, phosphodiesterase] 
 
CONCLUSION 
Herein, we have made an effort to review recent trends in AD. The 
molecular heredities of AD and the role of key proteins, oxidative 
damage, mitochondrial dysfunction and the cholinergic hypothesis 
that are assumed to contribute in AD pathogenesis are significant 
fields for advanced research. There is significant active investigation 
ongoing in the development of new inhibitors for BACE, kinase, and γ-
secretase as targets for treatment of AD. Thus, it is hoped that all these 
lines of ongoing research, combined, should lead to a deeper 
understanding of the progressions that happen in the AD brain to permit 
us to preclude efficiently their incidence. Thus, we conclude that these 
categories of drugs discussed in this review can be potentially targeted 
for research and development for the treatment of AD. 
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